Hyperlipidemia Market Opportunities And Strategies 2024-2033 - Growth Analysis, Outlook, Overview

The hyperlipidemia market size has grown steadily in recent years. It will grow from $19.41 billion in 2023 to $20.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.

The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $23.25 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.

Market Overview -
Hyperlipidemia is a medical condition characterized by abnormally high levels of lipids (fats) in the blood, including cholesterol and triglycerides. It is a common metabolic disorder and a significant risk factor for cardiovascular diseases.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

Elevating Demand In The Hyperlipidemia Market Driven By Rising Incidences Of Heart Disease
Increasing incidences of chronic disorders such as heart disease are expected to propel the growth of the hyperlipidemia market going forward. Heart diseases refer to diseases that affect the heart and its functioning. Hyperlipidemia treatment helps people suffering from heart disease by lowering the risk of heart attacks, preventing strokes, improving endothelial function and reducing the need for invasive interventions. For instance, in March 2022, according to a report published by The Office for National Statistics, a UK-based government department, the number of deaths due to heart attacks increased from 19,440 in 2020 to 20,061 in 2021. Therefore, increasing incidences of chronic disorders such as heart disease drive the growth of the hyperlipidemia market.

Competitive Landscape -
Major players in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

Innovative Products Drive Competitive Advantage For Leading Companies In The Hyperlipidemia Market
Major companies operating in the hyperlipidemia market are focused on developing innovative products, such as advanced lipid-lowering therapies, to sustain their position in the market. For example, in December 2021, Novartis, a US-based pharmaceutical company, launched a new hyperlipidemia drug called Leqvio (inclisiran), approved by the Food and Drug Administration, a US-based government agency. This is the first-in-class siRNA (small interfering RNA) drug that is used to lower cholesterol as an adjunct treatment to diet and statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Key Segments -

The hyperlipidemia market covered in this report is segmented -
1) By Type: Familial; Acquired
2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment
3) By Route of Administration: Oral; Parenteral
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.